Pacira BioSciences, Inc.
Rank #95HypergrowthPCRX · Nasdaq · Healthcare
Pacira BioSciences, Inc. (PCRX) — Rank #95 by gross profitability (GP/assets 0.46) · ROE 1.0% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001396814 · all metrics point-in-time as of the filing date.
About
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Show moreShow less
The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc.
was incorporated in 2006 and is headquartered in Brisbane, California.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- pacira.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2021-12-31filed 2022-02-28 | 2020-12-31filed 2021-03-01 | 2019-12-31filed 2020-02-21 | 2018-12-31filed 2019-02-28 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 28.5 | 19.9 | 19.6 | 13.2 |
| Stock-based compensation | 42.2 | 39.9 | 33.7 | 31.7 |
| Change in receivables | 10.4 | 5.5 | 8.5 | 6.0 |
| Change in inventory | 4.5 | 6.4 | 8.0 | 7.2 |
| Change in payables | (10.3) | (3.3) | (1.8) | (0.6) |
| Operating cash flow | 125.7 | 77.0 | 70.5 | 48.9 |
| Investing | ||||
| Capital expenditures | 45.9 | 37.8 | 10.2 | 14.5 |
| Acquisitions, net of cash | 0.0 | 0.0 | 117.7 | 0.0 |
| Investing cash flow | (20.8) | (277.6) | (128.5) | 20.6 |
| Financing | ||||
| Debt issued | — | — | — | — |
| Debt repaid | — | — | — | — |
| Financing cash flow | 380.7 | 222.3 | 3.7 | 9.0 |
| Summary | ||||
| Free cash flow | 79.9 | 39.2 | 60.4 | 34.4 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?